References
- Arzilli G, De Vita E, Pasquale M, et al. Innovative techniques for infection control and surveillance in hospital settings and long-term care facilities: A scoping review. Antibiotics 2024; 13(1): 77. doi:10.3390/antibiotics13010077.
- Belay WY, Getachew M, Tegegne BA, et al. Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: A review. Front Pharmacol. 2024; 15: 1444781. doi:10.3389/fphar.2024.1444781.
- Bereanu AS, Bereanu R, Mohor C, et al. Prevalence of infections and antimicrobial resistance of ESKAPE group bacteria isolated from patients admitted to the intensive care unit of a county emergency hospital in Romania. Antibiotics. 2024; 13(5): 400. doi:10.3390/antibiotics13050400.
- Chetri S. The culmination of multidrug-resistant efflux pumps vs. meager antibiotic arsenal era: Urgent need for an improved new generation of EPIs. Front. Microbiol. 2023; 14: 1149418. doi.org/10.3389/fmicb.2023.1149418.
- Cheung JRN. Nosocomical Infection. What Is It, Causes, Prevention, and More. https://www.osmosis.org/answers/nosocomial-infection [dostęp: 20.07.2021].
- Cimen C, Berends MS, Bathoorn E, et al. Vancomycin-resistant enterococci (VRE) in hospital settings across European borders: a scoping review comparing the epidemiology in the Netherlands and Germany. Antimicrob Resist Infect Control. 2023; 12(1): 78. doi:10.1186/s13756–023–01278–0.
- Coll F, Blane B, Bellis KL, et al. The mutational landscape of Staphylococcus aureus during colonisation. Nat Commun. 2025; 16(1): 302. doi:10.1038/s41467–024–55186-x.
- Dulanto Chiang A, Dekker JP. Efflux pump-mediated resistance to new Beta lactam antibiotics in multidrug-resistant gram-negative bacteria. Commun Med. 2024; 4(1): 170. doi:10.1038/s43856–024–00591-y.
- Dzierżanowska D. Antybiotykoterapia praktyczna. 6. wyd. BielskoBiała: Alfa-Medica Press. 2024.
- Eatemadi A, Al Risi E, Kasliwal A K, et al. A proposed evidence-based local guideline for definition of multidrug-resistant (MDR), extensively drug-resistant (XDR) and pan drug-resistant (PDR) bacteria by the Microbiology Laboratory. Int. J. Curr. Sci. Res. Rev. 2021; 4(3): 146–153. doi: 10.47191/ijcsrr/V4-i3–01
- Eichel VM, Last K, Brühwasser C, et al. Epidemiology and outcomes of vancomycin-resistant Enterococcus infections: a systematic review and meta-analysis. J HospInfect. 2023; 141: 119–128. doi.org/10.1016/j.jhin.2023.09.008.
- Elfadadny A, Ragab RF, AlHarbi M, et al. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front. Microbiol. 2024; 15: 1374466. doi.org/10.3389/fmicb.2024.1374466.
- Elshobary ME, Badawy NK, Ashraf Y, et al. Combating antibiotic resistance: Mechanisms, multidrug-resistant pathogens, and novel therapeutic approaches: An updated review. Pharmaceuticals. 2025; 18(3): 402. doi:10.3390/ph18030402.
- Floris I, Battistini R, Tramuta C, et al. Antibiotic resistance in Lactic Acid Bacteria from dairy products in Northern Italy. Antibiotics. 2025; 14(4): 375. doi:10.3390/antibiotics14040375.
- García-Díez J, Moura D, Grispoldi L, et al. Salmonella spp. in domestic ruminants, evaluation of antimicrobial resistance based on the One Health approach – A systematic review and meta-analysis. Vet Sci. 2024; 11(7): 315. doi:10.3390/vetsci11070315.
- Gross R, Yelin I, Lázár V, et al. Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance. Nat Commun. 2024; 15(1): 5383. doi:10.1038/s41467–024–49621–2.
- Gürbüz M, Gencer G. Global trends and future directions on carbapenem-resistant Enterobacteriaceae (CRE) research: A comprehensive bibliometric analysis (2020–2024). Med (Baltimore). 2024; 103(49): e40783. doi: 10.1097/MD.0000000000040783.
- Hasanpour AH, Sepidarkish M, Mollalo A, et al. The global prevalence of methicillin-resistant Staphylococcus aureus colonization in residents of elderly care centers: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2023; 12(1): 4. doi:10.1186/s13756–023–01210–6.
- Huang YS, Zhou H. Breakthrough advances in Beta-lactamase inhibitors: New synthesized compounds and mechanisms of action against drug-resistant bacteria. Pharmaceuticals (Basel). 2025; 18(2): 206. doi:10.3390/ph18020206.
- Huh K, Chung DR, Ha YE, et. al. Korean Antimicrobial Resistance Surveillance Network (KARS-Net) Investigators. Impact of vancomycin resistance in Enterococcus faecium bloodstream infection on mortality: a retrospective analysis of nationwide surveillance data. Int J Infect Dis. 2023; 134: 8–14. doi:10.1016/j.ijid.2023.04.411.
- Ibrahim S, Al-Saryi N, Al-Kadmy IMS, et al. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021; 48(10): 6987–6998. doi: 10.1007/s11033–021–06690–6.
- Jochim-Vukosavic A, Schwab F, Knegendorf L, et al. Epidemiology and infection control of vancomycin-resistant enterococci at a German university hospital: A three-year retrospective cohort study. Plos One. 2024; 19(2): e0297866. doi.org/10.1371/journal.pone.0297866.
- Krco S, Davis SJ, Joshi P, et al. Structure, function, and evolution of metallo-β-lactamases from the B3 subgroup – emerging targets to combat antibiotic resistance. Front Chem. 2023; 11:1196073. doi:10.3389/fchem.2023.1196073.
- Kuziemski A, Frankowska K, Gonia E. Etiologia zakażeń szpitalnych rejestrowanych w Szpitalu Uniwersyteckim nr 2 w Bydgoszczy w latach 2015–2017. Zakażenia XXI wieku. 2018; 1(5): 241–245. doi: 10.31350/zakazenia/2018/5/Z2018040.
- Leanza C, Mascellino M T, Volpicelli L, et al. Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: A single-center preliminary experience. Front. Microbiol. 2025; 15: 1432296. doi.org/10.3389/fmicb.2024.1432296.
- Li J, Wu W, Wu H, et al. Rapid emergence, transmission, and evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae. Microbiol Res. 2025; 293: 128049. doi: 10.1016/j. micres.2025.128049.
- Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. The Lancet. 2025; 405(10474): 257–272.
- Minter DJ, Appa A, Chambers HF, et al. Contemporary management of Staphylococcus aureus bacteremia – controversies in clinical practice. Clin Infect Dis. 2023; 77(11): e57-e68. doi.org/10.1093/cid/ciad500.
- Mlynarczyk-Bonikowska B, Kowalewski C, Krolak-Ulinska A, et al. Molecular mechanisms of drug resistance in Staphylococcus aureus. Int. J. Mol. Sci. 2022; 23(15): 8088. doi.org/10.3390/ijms23158088.
- Nowakowska MA. Cefalosporynazy AmpC u Escherichia coli AmpC cephalosporinases in Escherichia coli. Med. Dośw. Mikrobiol. 2021; 73: 53–69. doi.org/10.32394/mdm.73.05.
- O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations (HM Government and Wellcome Trust) [(accessed on 20 July 2019)]; 2014 Available online: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.
- Osińska M, Rysiak E, Zaręba R, et al. Zakażenia szpitalne w aspekcie prawnym. Anaesthesiology & Rescue Medicine/Anestezjologia i Ratownictwo 2018; 12(3).
- Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019 Jan-Feb; 37(1): 177–192. doi: 10.1016/j. biotechadv.2018.11.013.
- Pawilk K, Mączyńska A, Fleischer M, et al. Kontrola środowiska szpitalnego w zapobieganiu zakażeniom wywołanym przez wieloantybiotykooporne patogeny alarmowe. Narodowy Instytut Leków 2020.
- Punchihewage-Don AJ, Ranaweera PN, Parveen S. (2024). Defense mechanisms of Salmonella against antibiotics: a review.Front. Antibiot. 2024; 3: 1448796. doi:10.3389/frabi.2024.1448796.
- Rahman MK, Rodriguez-Mori H, Loneragan G, et al. One Health distribution of beta-lactamases in Enterobacterales in the United States: A systematic review and meta-analysis.International Int J Antimicrob Agents. 2025; 65(2): 107422. doi:10.1016/j.ijantimicag.2024.107422.
- Sajeev S, Hamza M, Rajan V, et al. Resistance profiles and genotyping of extended-spectrum beta-lactamase (ESBL)-producing and non-ESBL-producing E. coli and Klebsiella from retail market fishes. Infection. Genet. Sel. Evol. 2023; 112: 105446. doi.org/10.1016/j.meegid.2023.105446.
- Schmidt N, Marujo V, Eckmanns T, et al. Healthcare-associated infections and antimicrobial use in long-term care facilities. German results of the third European point prevalence survey HALT-3.Bundes-gesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2022; 65(9): 863–871. doi.org/10.1007/s00103–022–03566–3.
- Schwartz B, Klamer K, Zimmerman J, et al. Multidrug resistant Pseudomonas aeruginosa in clinical settings: A review of resistance mechanisms and treatment strategies. Pathogens. 2024; 13(11): 975. doi:10.3390/pathogens13110975.
- Shi J, Cheng J, Liu S, et al. Acinetobacter baumannii: an evolving and cunning opponent. Front. Microbiol. 2024; 15: 1332108. doi.org/10.3389/fmicb.2024.1332108.
- Skarżyńska M, Zając M, Wasyl D. Antibiotics and bacteria: Mechanisms of action and resistance strategies. Post Mikrobiol – Advancements of Microbiology. 2020; 59(1): 49–62. doi:10.21307/PM-2020.59.1.005.
- Stec J, Kosikowska U. Problem transmisji czynników lekooporności, ze szczególnym uwzględnieniem oporności na antybiotyki z grupy β-laktamów, u bakterii Gram-ujemnych. Medycyna XXI wieku. Mono-grafia naukowa. 2019; 84–91.
- Stewart A, Harris P, Henderson A, et al. Treatment of Infections by OXA-48-Producing Enterobacteriaceae. Antimicrob. Agents Chemother. 2018; 62(11): e01195–18. doi: 10.1128/AAC.01195–18.
- Suay-García B, Pérez-Gracia MT. Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics (Basel). 2019 Aug 19; 8(3): 122. doi: 10.3390/antibiotics8030122.
- Suetens C, Plachouras D. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals, 2022–2023. European Centre for Disease Prevention and Control. Stockholm: ECDC; 2024 May. doi:10.2900/88011.
- Thomsen J, Abdulrazzak NM, AlRand H, et al. Epidemiology of vancomycin-resistant enterococci in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data. Front. Public Health. 2023; 11: 1275778. doi:10.3389/fpubh.2023.1275778.
- Trześniewska-Ofiara Z, Mendrycka M, Cudo A, et al. Hospital Urinary Tract Infections in Healthcare Units on the Example of Mazovian Specialist Hospital Ltd. Front Cell Infect Microbiol. 2022; 12: 915288. doi: 10.3389/fcimb.2022.891796.
- Van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017; 8: 460–469. doi: 10.1080/21505594.2016.1222343.
- Wałaszek MZ. Zakażenia szpitalne-czy potrafimy im zapobiegać. Biuletyn Głównej Biblioteki Lekar-skiej (Warszawa). 2019; 52(4): 79–118.
- World Health Organization. WHO publishes list of bacteria for which now antibiotics are urgently needed. Available from: https://www.who.int/news/item/27–02–2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed January 20, 2022.
- Yao Z, Wu Y, Xu H, et al. Prevalence and clinical characteristics of methicillin-resistant Staphylococcus aureus infections among dermatology inpatients: A 7-year retrospective study at a tertiary care center in southwest China. Front. Public Health. 2023; 11: 1124930. doi.org/10.3389/fpubh.2023.1124930.
- Zhang S, Xiao J, Li Y, et al. An integrative review on the risk factors, prevention, and control strategies for carbapenem-resistant Acinetobacter baumannii colonization in critically ill patients. Front. Microbiol. 2025; 15: 1519906. doi:10.3389/fmicb.2024.1519906.
- Zhu Y, Huang WE, Yang Q. Clinical perspective of antimicrobial resistance in bacteria. Infet Drug Resist. 2022 Mar 2; 15: 735–746. doi: 10.2147/IDR.S345574.